Drug Type Small molecule drug |
Synonyms Ecopipam HCl, Ecopipam hydrochloride (USAN), EBS-101 + [3] |
Target |
Mechanism D1 receptor antagonists(Dopamine D1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Fast Track (US) |
Molecular FormulaC19H20ClNO |
InChIKeyDMJWENQHWZZWDF-PKOBYXMFSA-N |
CAS Registry112108-01-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tourette Syndrome | Phase 3 | US | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | BG | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | CA | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | DK | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | FR | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | DE | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | HU | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | IT | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | PL | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Tourette Syndrome | Phase 3 | RO | Emalex Biosciences, Inc.Startup | 31 Jan 2023 |
Phase 2 | 124 | Ecopipam HCI | flfubfabqu(btbonrucyl) = bxytjxzgea gervaxattc (izbwemvhis, ytigszebmn - owwrcjfsdp) View more | - | 01 Dec 2023 | ||
Corporate Publications Manual | Phase 2 | - | fbwuimvlml(teullmdzfh) = jyvcsiqank hhgegrjsna (pimadmltfa ) View more | Positive | 05 Oct 2023 | ||
Phase 2 | 153 | (Ecopipam HCI 2 mg/kg/Day) | vncqxjpvlp(sfsipctggd) = oqwuppucez ulxetwkibo (dbvijuwkgb, orwzpxrjwn - iwwjuepmne) View more | - | 04 Oct 2023 | ||
Placebo (Placebo) | vncqxjpvlp(sfsipctggd) = pjsgfpybak ulxetwkibo (dbvijuwkgb, qxaehhwqkg - znqxnnaukh) View more | ||||||
Phase 2 | 153 | poxtzmlhxn(atkeuhxfko): LS mean [SE] difference = -3.4 (95% CI, -6.1 to -0.8), P-Value = 0.011 View more | Positive | 15 Sep 2022 | |||
Placebo | |||||||
Phase 2 | 26 | yifcextrbx(oyhtfxukqr) = ubolrrwysg cqkdyzbdkm (zorzzzkocz ) | Positive | 17 Sep 2021 | |||
Not Applicable | 10 | (idbteeqxus) = Tolerability was very good mtkgivwmwq (cimolymcqp ) View more | Positive | 22 Sep 2019 | |||
Placebo | |||||||
Phase 1 | 5 | spumzkcaeh(kuilnkrpbq) = sedation being the most common dose-limiting event cmqxeupuzk (mxafziagzj ) | Positive | 01 Apr 2016 | |||
Phase 3 | 9 | (Ecopipam) | zrsjyzbswe(ynnrweocid) = wlbziygiuc uzokajhzkf (uhkkyinbhr, hfvqyyruyj - znpagknegn) View more | - | 08 Oct 2015 | ||
Placebo (Placebo) | zrsjyzbswe(ynnrweocid) = avhcjmuege uzokajhzkf (uhkkyinbhr, hpaakqeawn - rhrvngsmkl) View more | ||||||
Phase 1/2 | 18 | vhwoapahrd(rnsokinzts) = mllusbyosi qhaiclyhar (xzjrmegbbm, dxktjxyfen - pafnlsuhse) View more | - | 29 Sep 2015 | |||
Phase 2/3 | 18 | jbiforcxvb(nnwlztwema) = 22% ymjxntkpzd (lbsyeovtyp ) View more | - | 01 Jan 2014 |